Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2020 Sep 21

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Medica 2020 Sep 21

DOI: 10.23736/S0026-4806.20.07019-6

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and feature

MIchele GOTTARDI 1 , Alessandra SPEROTTO 2, Andrea GHELLI LUSERNA DI RORÁ 3, Antonella PADELLA 3, Delia CANGINI 4, Maria Benedetta GIANNINI 4, Giorgia SIMONETTI 3, Giovanni MARTINELLI 5, Claudio CERCHIONE 4

1 Istituto Oncologico Veneto-IRCCS, Padua, Italy; 2 Hematology and Transplant Center Unit, Udine University Hospital, Dipartimento di Area Medica (DAME), University of Udine, Udine, Italy; 3 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Forlì-Cesena, Italy; 4 Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Forlì-Cesena, Italy; 5 Scientific Directorate, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Forlì-Cesena, Italy


PDF


After being in the therapeutic wilderness for several decades, acute myeloid leukaemia has been recently thrust into the limelight with a series of drug approvals. Technical refinements in production, genetic manipulation and chemical modification of monoclonal antibodies led to growing interest in antibodies-based treatment strategies. Much of the focus of these efforts in acute myeloid leukemia has been on CD33 as a target. On September 2, 2017, the U.S. Food and Drug Administration approved Gemtuzumab Ozogamicin for treatment of relapsed or refractory CD33+ acute myeloid leukemia. This signals a new chapter in the long and unusual story of Gemtuzumab Ozogamicin, which was the first antibody-drug conjugate approved for human use by the Food and Drug Administration. In this review we have analyzed the history of this drug which, among several mishaps, is experiencing a second youth and still represents a field to be further explored.


KEY WORDS: Acute myeloid leukemia; Gemtuzumab ozogamicin; Clinical trials; Biomarkers

top of page